Carbamazepine toxicity after starting combination antiretroviral therapy including ritonavir and efavirenz

AIDS. 2000 Dec 1;14(17):2793-4. doi: 10.1097/00002030-200012010-00022.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Alkynes
  • Anti-HIV Agents / pharmacology
  • Anti-HIV Agents / therapeutic use*
  • Anticonvulsants / administration & dosage
  • Anticonvulsants / adverse effects
  • Anticonvulsants / metabolism
  • Anticonvulsants / therapeutic use
  • Antiretroviral Therapy, Highly Active
  • Benzoxazines
  • Carbamazepine / administration & dosage
  • Carbamazepine / adverse effects*
  • Carbamazepine / metabolism
  • Carbamazepine / therapeutic use
  • Cyclopropanes
  • Cytochrome P-450 CYP3A
  • Cytochrome P-450 Enzyme Inhibitors
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Female
  • HIV Infections / complications*
  • HIV Infections / drug therapy*
  • HIV Protease Inhibitors / pharmacology
  • HIV Protease Inhibitors / therapeutic use
  • Humans
  • Middle Aged
  • Mixed Function Oxygenases / antagonists & inhibitors
  • Oxazines / pharmacology
  • Oxazines / therapeutic use*
  • Reverse Transcriptase Inhibitors / therapeutic use
  • Ritonavir / pharmacology*
  • Ritonavir / therapeutic use
  • Seizures / complications
  • Seizures / drug therapy

Substances

  • Alkynes
  • Anti-HIV Agents
  • Anticonvulsants
  • Benzoxazines
  • Cyclopropanes
  • Cytochrome P-450 Enzyme Inhibitors
  • HIV Protease Inhibitors
  • Oxazines
  • Reverse Transcriptase Inhibitors
  • Carbamazepine
  • Mixed Function Oxygenases
  • CYP3A protein, human
  • Cytochrome P-450 CYP3A
  • efavirenz
  • Ritonavir